Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KPCXM18 in acute ischemic stroke
NCT07279493Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ginsenotriol disuccinate sodium in ischemic stroke (3 arms). Primary endpoint: Modified Rankin Scale at 90 days. Started Nov 2025; status: recruiting.
02
Drugs
ginsenotriol disuccinate sodium
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07279493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279493.